Skip to main content
SpringerLink
Log in

Keine Nitrattoleranz nach kontinuierlicher oraler Gabe von PETN

  • Chapter
Pentaerithrityltetranitrat

  • 18 Accesses

Zusammenfassung

Wie eine Studie am Cholesterol-gefütterten Kaninchen gezeigt hat, führt die Behandlung mit einer Einzeldosis von 6 mg PETN/kg KG/Tag bei bereits etablierter Atherosklerose zu:

  • einer signifikanten Verringerung der Fläche der atherosklerotischen Läsionen in der thorakalen Aorta

  • einer Verhinderung der Progression der endothelialen Dysfunktion (keine weitere Einschränkung der endothelabhängigen Relaxation trotz drastischer Hypercholesterolämie)

  • einer signifikanten Verringerung der Oxidation von LDL in vivo.

Handelsname: Pentalong®

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 44.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlner J, Andersson RGG, Torfgârd K, Axelsson KL (1991) Organic nitrate esters: Clinical use and mechanisms of actions. Pharmacol Rev 43: 351–423

    PubMed  CAS  Google Scholar 

  2. Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG (2000) Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 105: 1631–1639

    Article  PubMed  CAS  Google Scholar 

  3. Gruppo Italiano per to Studio della Sopravvivenza nell’Infarto Miocardico (1994) GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115–1122

    Google Scholar 

  4. Hacker A, Noack E, Kojda G (2000) Continuous treatment with pentaerythritol tetranitrate prevents the increase of LDL-oxidation in established atherosclerosis. In: Navaro-Lopez F (ed) XXI Congress of the European Society of Cardiology. Monduzzi Editore, Italy, p 251–257

    Google Scholar 

  5. ISIS-4 Collaborative Group (1995) ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 345: 669–685

    Google Scholar 

  6. Kojda G, Hacker A, Noack E (1998) Effects of non-intermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and vascular superoxide production. Eur J Pharmacol 355: 23–31

    Article  PubMed  CAS  Google Scholar 

  7. Kojda G, Harrison DG (1999) Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43: 562–571

    Article  PubMed  CAS  Google Scholar 

  8. Kojda G, Stein D, Kottenberg E, Schnaith EM, Noack E (1995) In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 25: 763–773

    Article  PubMed  CAS  Google Scholar 

  9. Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB (1996) Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 271: 40–47

    Article  PubMed  CAS  Google Scholar 

  10. Münzel T, Harrison DG (1997) Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J Mol Med 75: 891–900

    Article  PubMed  Google Scholar 

  11. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187–194

    Google Scholar 

  12. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187–194

    Google Scholar 

  13. Parker JD, Parker JO (1998) Nitrate therapy for stable angina pectoris. N Engl J Med 338: 520–531

    Article  PubMed  CAS  Google Scholar 

  14. Weber W, Michaelis K, Luckow V, Kuntze U, Stalleicken D (1995) Pharmacokinetics and bioavailability of pentaerythrityl tetranitrate and two of its metabolites. Arzneim Forsch 45: 781–784

    CAS  Google Scholar 

Download references

Authors
  1. Senta Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Müllenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ute Laber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Thämer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Kojda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie — Angiologie — Pneumologie und internistische Intensivmedizin, Joseph-Stelzmann-Straße 9, 50924, Köln (Lindenthal), Deutschland

    E. Erdmann

  2. Fachbereich Pharmazie, Institut für Pharmakologie und Toxikologie für Naturwissenschaftler, Wolfgang-Langenbeck-Straße 4, 06120, Halle, Deutschland

    H. Schröder

  3. Arbeitsgruppe Pharmakologie, Hochschule für Technik und Wirtschaft (FH) Albstadt-Sigmaringen, ALPHARMA-ISIS GmbH & Co. KG, Langenfeld, Deutschland

    D. Stalleicken (Medizinischer Direktor, Mitglied) (Medizinischer Direktor, Mitglied)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Müller, S. et al. (2001). Keine Nitrattoleranz nach kontinuierlicher oraler Gabe von PETN. In: Erdmann, E., Schröder, H., Stalleicken, D. (eds) Pentaerithrityltetranitrat. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-87802-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-87802-2_7

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-7985-1315-0

  • Online ISBN: 978-3-642-87802-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation